Peptide and related-compound status in Canada and the United States.

Health Canada-authorized products exist; verify the DIN and product monograph.

FDA-approved products exist; compounded versions are not FDA-approved generics.

Authorized prescription products appear in Health Canada’s Drug Product Database.

FDA-approved products exist; approval applies to specific products and labels.

Authorized products exist; confirm current marketed status and indication in the Drug Product Database.

FDA-approved products exist; use the current product label for risk and indication details.

No Health Canada-authorized product identified in the current source review.

Not FDA approved; FDA states it cannot be used in compounding under federal law.

No authorized human drug identified in the current source review.

No FDA-approved product; FDA describes limited safety information and characterization concerns.

No authorized human drug identified in the current source review.

No FDA-approved product; FDA notes limited data and serious adverse-event reports.

Health Canada lists injectable TB-500 among unauthorized peptide drugs and advises consumers not to buy or use such products.

No FDA-approved product. FDA describes absent human exposure data plus immunogenicity and peptide-impurity concerns.

Health Canada lists injectable GHK-Cu among unauthorized peptide drugs. Cosmetic status depends on formulation and claims and is not injectable-drug authorization.

No FDA-approved injectable product. FDA identifies limited human safety data and aggregation, impurity, and immunogenicity concerns for injectable routes.

Health Canada lists injectable KPV among unauthorized peptide drugs and states that unauthorized drugs have not been assessed for safety, efficacy, or quality.

No FDA-approved product. FDA states it has not identified human exposure data and lacks information needed to assess harm.

Health Canada records show prior EGRIFTA DINs, but the reviewed 1 mg and 2 mg records are canceled. Verify the live database before treating any product as currently marketed.

EGRIFTA SV is FDA approved for a specific HIV-lipodystrophy indication. Approval and reconstitution instructions apply to that labeled product, not generic research vials.

Health Canada lists injectable ipamorelin among unauthorized peptide drugs; no authorized human product was identified in the current review.

No FDA-approved product. FDA identifies characterization and immunogenicity concerns and limited safety information for injectable routes.

Health Canada lists injectable Epitalon among unauthorized peptide drugs and warns that these products have not been assessed for safety, efficacy, or quality.

No FDA-approved product identified in the current authorization-database review. FDA lists Epitalon among withdrawn bulk-drug-substance nominations and says it lacks sufficient safety information to know whether compounded use would harm humans.

Health Canada lists injectable MOTS-c among unauthorized peptide drugs and advises consumers not to buy or use them.

No FDA-approved product. FDA cites absent human exposure data plus peptide characterization and immunogenicity concerns.

No Health Canada-authorized cagrilintide product was identified in the current Drug Product Database review. Canadian trial activity is research activity, not market authorization.

Not FDA approved. FDA states that cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.

No Health Canada-authorized bremelanotide product was identified in the current Drug Product Database review. Verify the live database before relying on this status.

Vyleesi is FDA approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Approval applies to that product and label—not to generic PT-141 powder or products sold for other purposes.

No Health Canada-authorized human drug was identified in the current Drug Product Database review.

No FDA-approved product was identified. FDA describes peptide-impurity and immunogenicity concerns and says important human safety information is lacking for selank acetate.

No Health Canada-authorized human drug was identified in the current Drug Product Database review.

No FDA-approved product was identified. FDA describes aggregation, peptide-impurity, and immunogenicity concerns and says safety information is absent or limited for proposed routes.

No authorized injectable glutathione drug was identified in the current Drug Product Database review. Health Canada has reported unauthorized glutathione injections associated with excessive endotoxin; separately licensed natural health products do not authorize injection.

No FDA-approved injectable glutathione product was identified. FDA has reported adverse events and excessive endotoxin associated with dietary-grade glutathione used to compound sterile injectables.

NAD+ is not a peptide. Health Canada lists unauthorized injectable NAD+ among products of concern, and no authorized NAD+ injectable drug was identified in the current Drug Product Database review.

No FDA-approved NAD+ injectable product was identified. FDA has warned that food-grade NAD+ is unsuitable for sterile compounding and has received adverse-event reports following injectable NAD+ products.